Substituted 4-methylcoumarin inhibitors of SLC26A3 (DRA) for treatment of constipation and hyperoxaluria is a research paper published in RSC Medicinal Chemistry (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: DK072517
National Institute of Diabetes and Digestive and Kidney Diseases
Grant: DK126070
University of California, San Francisco
Grant: UL1 TR001872
National Eye Institute
Grant: EY036139
NIDDK NIH HHS
Grant: P30 DK072517
NIDDK NIH HHS
Grant: R01 DK126070
NEI NIH HHS
Grant: R01 EY036139
National Institutes of Health
Grant: 5R01DK126070-05
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and Nephrolithiasis
National Institutes of Health
Grant: 5UL1TR001872-02
Clinical and Translational Science Institute
Cystic Fibrosis Foundation
FWCI
0.67
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals